In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

VT-1129 is a novel fungal enzyme-specific Cyp51 inhibitor with potent cryptococcal activity. Because of its long half-life (>6 days in mice) and our desire to quickly reach potent efficacy, we evaluated a VT-1129 loading dose-maintenance dose strategy against cryptococcal meningitis. VT-1129 plas...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Antimicrob Agents Chemother
Hoofdauteurs: Wiederhold, Nathan P., Xu, Xin, Wang, Amy, Najvar, Laura K., Garvey, Edward P., Ottinger, Elizabeth A., Alimardanov, Asaf, Cradock, Jim, Behnke, Mark, Hoekstra, William J., Brand, Stephen R., Schotzinger, Robert J., Jaramillo, Rosie, Olivo, Marcos, Kirkpatrick, William R., Patterson, Thomas F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Microbiology 2018
Onderwerpen:
Experimental Therapeutics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201077/
https://ncbi.nlm.nih.gov/pubmed/30104280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01315-18
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items